GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT05445232

CompletedPhase 1

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 27-40

Primary endpoints

•AUC From Zero to Infinity (AUC[0-∞]) of Midazolam•PK: Maximum Observed Concentration (Cmax) of Midazolam•PK: AUC[0-∞] of Warfarin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05445232

Org study ID18476

Secondary IDJ1I-MC-GZBIEli Lilly and Company

Timeline

Milestones

Study first posted2022-07-06actual

Study start2022-07-08actual

Primary completion2023-02-24actual

Study completion2023-02-24actual

Last update posted2023-04-18actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)

•Male and female participants of childbearing potential who agree to use contraceptive methods

Exclusion criteria

•Have a history of diabetes or current diagnosis of diabetes

•History or presence of a of significant bleeding disorder

•Participants with significant comorbidity

•Participants receiving treatment with midazolam, warfarin, inhibitors or inducers of cytochrome P450 (CYP) -1A2, CYP2C9, or CYP3A4 enzymes, or drugs are CYP substrates and have a narrow therapeutic index

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

6 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam

Time frame:Predose up to 24 hours postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Maximum Observed Concentration (Cmax) of Midazolam

Time frame:Predose up to 24 hours postdose

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: AUC[0-∞] of Warfarin

Time frame:Predose up to 96 hours postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Warfarin

Time frame:Predose up to 96 hours postdose

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: AUC[0-∞] of Caffeine

Time frame:Predose up to 48 hours postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Cmax of Caffeine

Time frame:Predose up to 48 hours postdose

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.